AGEX THERAPEUTICS INC
Stem cell-derived exosomes for peripheral artery disease treatment
Updated · agexinc.com
- Sector
- Biotech
- Headquarters
- Alameda, CA
- Founded
- 2017
- Latest Form D
- $4.5M, Mar 2019
- Total capital
- $20M
- Grants
- $566K
- 2 awards
- 2.0× sector median 1 award
- Raised
- $19M
- 5 Form D · Mar 2019
- 91 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 0 granted · 24 pending
- 12× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery Disease | $340,956 | |
| Private capital raised | Form D · SEC | $4,500,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Metabolically Reprogrammed Mesenchymal Stem Cells for Treating Osteoporosis | $224,973 | |
| Private capital raised | Form D · SEC | $200,000 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $462,500 | |
| Private capital raised | Form D · SEC | $8,850,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3382 | Colossal Biosciences | — | $150M |
| 3383 | PepGen Inc. | — | $127M |
| 3384 | MouSensor, Inc. | — | — |
| 3385 | AGEX THERAPEUTICS INC | — | $19M |
| 3386 | Ultragenyx Pharmaceutical Inc. | — | $109M |
| 3387 | BlueSphere Bio, Inc. | — | $56M |
| 3388 | Life Biosciences LLC | — | $54M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gregory BaileyDirector
- Not Applicable BioTime, Inc.Promoter
- Annalisa JenkinsDirector
- Alfred KingsleyDirector · Executive Officer
- John MauldinDirector
- Michael MulroyDirector
- Russell SkibstedExecutive Officer
- Michael WestDirector · Executive Officer
Patents
- Compositions And Methods For Detecting Cardiotoxicityapplication
- Methods For Modulating The Regenerative Phenotype In Mammalian Cellsapplication
- Methods And Compositions Used To Modify Chromatin Architecture To Regulate Phenotype In Aging And Cancerapplication
- Methods For The Ex Vivo Induction Of Tissue Regeneration In Microbiopsiesapplication
- Methods For Generating Pluripotent Stem Cell-derived Brown Fat Cellsapplication
- Pericyte Cell Exosomesapplication
- Differentially-methylated Regions Of The Genome Useful As Markers Of Embryo-adult Transitionsapplication
- Methods For Detecting And Modulating The Embryonic-fetal Transition In Mammalian Speciesapplication
- Methods For Detecting And Modulating The Embryonic-fetal Transition In Mammalian Speciesapplication
- Methods For Detecting And Modulating The Embryonic-fetal Transition In Mammalian Speciesapplication
- Therapeutic Exosomes And Method Of Producing Themapplication
- Improved Methods For Inducing Tissue Regeneration And Senolysis In Mammalian Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.